Aquestive Therapeutics vs Aytu BioPharma
AQST and AYTU side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and AYTU compare
Aquestive Therapeutics is the larger company, worth 25 times as much as Aytu BioPharma ($491M against $19.3M).
Aquestive Therapeutics grew revenue faster over the last twelve months (12.5% versus −13.3% for Aytu BioPharma).
Aytu BioPharma keeps more of each dollar of sales as profit, with a net margin of −24.8% compared with −162% at Aquestive Therapeutics.
Aytu BioPharma scores higher on the StockData Score (9 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | AYTU |
|---|---|---|
| Size and price | ||
| Market cap | $491M | $19.3M |
| Share price | $3.91 | $1.78 |
| Change, 1 year | −29.9% | −13.6% |
| Change, 5 years | −34.5% | −95.6% |
| Beta (5Y) | 1.45 | 1.05 |
| Employees | 147 | 76 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.0× | 0.3× (better) |
| P/B | – | 0.5× |
| P/FCF | – | 5.9× |
| FCF yield | −8.3% | 16.8% (better) |
| Fair value | – | $8.51 |
| Margin of safety | – | 79.1% |
| Growth | ||
| Revenue growth (TTM) | 12.5% (better) | −13.3% |
| Revenue growth, 5Y average | −0.58% (better) | −2.6% |
| Profitability | ||
| Gross margin | 65.3% (better) | 64.0% |
| Operating margin | −114% | −14.4% (better) |
| Net margin | −162% | −24.8% (better) |
| FCF margin | −83.3% | 5.6% (better) |
| Return on equity | – | −52.6% |
| Return on invested capital | – | −63.5% |
| Financial health | ||
| Debt / equity | – | 0.31 |
| Interest coverage | −5.4× | −4.4× (better) |
| Current ratio | 6.12 (better) | 1.13 |
| Altman Z-score | −4.49 | −4.10 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 45.3% |
| Held by insiders | 3.2% | 15.1% |
| Insider net buying, 12 months | −$2.3M | – |
| Short interest, % of float | 24.1% | 3.3% |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- AYTU stock overview
- AYTU income statement
- AYTU valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.